Understanding the Condition
The parents' question about long-term management is a key teaching moment.
Congenital adrenal hyperplasia (CAH), most commonly caused by
21-hydroxylase deficiency (21OHD), is an autosomal recessive disorder characterized by impaired cortisol synthesis and excess adrenal androgen production [1,2]. This is not a transient condition; it results from a genetic mutation in the
CYP21A2 gene that permanently affects the adrenal glands' ability to produce cortisol and, in many cases, aldosterone
[4]. Therefore, explaining that the condition will resolve on its own is inaccurate and could lead to life-threatening adrenal crisis.
Analyzing the Priority Intervention
The priority nursing intervention is to educate the parents about lifelong hormone replacement therapy and stress management. The foundational goal of pharmacotherapy in CAH is to replace the deficient hormones while minimizing the adverse effects of treatment [1,2]. This requires a dual approach for patients with the salt-wasting form of classical CAH.
First,
glucocorticoid replacement (e.g., hydrocortisone) is necessary to replace the missing cortisol. This serves a dual purpose: preventing adrenal crisis and, through negative feedback on the pituitary gland, suppressing the overproduction of adrenal androgens
[1]. Achieving this balance is challenging, as supraphysiologic doses are often required to suppress androgens, which carries a risk of long-term morbidity
[1]. Parents must be taught the critical importance of daily medication adherence, never abruptly stopping the medication, and recognizing signs of both under-replacement (adrenal crisis) and over-replacement (Cushingoid features).
Second,
mineralocorticoid replacement (fludrocortisone) is required to replace aldosterone in salt-wasting CAH. This hormone is essential for sodium and fluid balance. Restricting sodium intake would be a dangerous intervention for an infant with salt-wasting CAH, as they are at risk for life-threatening hyponatremia and hyperkalemia. Instead, treatment involves fludrocortisone and often sodium chloride supplementation, especially in infancy [3,4]. Research is even focused on precision dosing of fludrocortisone to prevent long-term complications like hypertension from excessive replacement
[3].
Finally, the concept of
stress management is inseparable from hormone replacement. During physiological stress (e.g., fever, infection, surgery), the body's demand for cortisol increases dramatically. Parents must be educated on "sick day rules," which involve significantly increasing or even injecting the glucocorticoid dose to prevent an adrenal crisis. This is a cornerstone of safe, long-term management
[1]. Surgical intervention is not a first-line treatment to correct the underlying enzymatic deficiency; it is reserved for specific anatomical concerns in affected females and is not the immediate priority in a newly diagnosed infant.
Why Other Options Are Incorrect
-
Option 1: CAH is a genetic, lifelong disorder requiring continuous management; it does not resolve with age [1,4].
-
Option 2: Sodium restriction is contraindicated, particularly in salt-wasting CAH, where the body loses excessive sodium. Management involves mineralocorticoid and often sodium replacement
[3].
-
Option 4: Immediate surgical intervention is not a treatment for the hormonal imbalance itself. Management is centered on pharmacotherapy to replace deficient hormones and suppress excess androgens [1,2].
The core of long-term CAH management is a comprehensive understanding of lifelong, dual hormone replacement and the dynamic adjustment required during illness to prevent life-threatening crises [1,2,3].
References (research sources)
- [1]
Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.Research articleGoai WH, Torpy DJ. (2026) · DOI: 10.1080/14656566.2026.2695099
- [3]
Precision Management of Fludrocortisone-Related Hypertension Risk in Congenital Adrenal Hyperplasia: A Machine Learning Approach to Personalized DosingResearch articleDu S, Chen Z, Zhu G, Li T, Deng W, Ji W, Yuan Y, Ba Y, Wang X, Li R. (2026) · DOI: 10.64898/2026.07.22.26358644
- [4]
Congenital adrenal hyperplasia in Saudi Arabia: Epidemiology, genetic mutations, and evolving management strategies.Research articleAl-Agha AE, Abukammas SJ. (2026) · DOI: 10.1016/j.jnma.2026.02.006